About
Access for Life aims to facilitate repetitive therapies requiring vascular access for patients with chronic diseases. The companys patented JEM device acts as a smart needle guide and is designed to preserve the vessel wall and reduce the rate of clinical complications due to vessel wall damage (e.g. perforation, pseudoaneurysms, hematomas, and infection), reducing morbidity and mortality as well as healthcare costs. The device is designed to allow for easier and safer repetitive vascular access, particularly for hemodialysis and eventually for chemotherapy. The JEM smart device attaches directly to an arterio-venous (AV) fistula or graft and is implanted in the subcutaneous tissue directly beneath the skin. It provides safer and easier repeated insertion of needles for vascular access and prevents unintended vein perforation and bleeding. The device requires much less skill for proper needle insertion, encourages home and self-care hemodialysis, and can use a blunt needle for pain reduction. It could also replace the chemoport currently used for chemotherapy. In addition, Access for Life has added sensors which allow ultrasound and velocity measurements to provide clinical data to clinicians and patients and to enable dialysis-related big data analysis.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Access For Life's primary product?
- Access For Life's primary product is the JEM device, a patented subcutaneous implanted device designed to facilitate repetitive vascular access for patients with chronic diseases.
- What is the main purpose of the JEM device?
- The JEM device acts as a smart needle guide, aiming to preserve the vessel wall, reduce clinical complications from vessel wall damage, and enable easier and safer repetitive vascular access for therapies like hemodialysis and potentially chemotherapy.
- When was Access For Life founded?
- Access For Life was founded in September 2013.
- Where is Access For Life headquartered?
- Access For Life is headquartered in Netanya, Israel, at HaGra 11.
- When did Access For Life receive its Seed funding?
- Access For Life received Seed funding in January 2016, with Pharmes Innovations Limited listed as an investor.
- Has Access For Life received any grants?
- Yes, Access For Life received a grant from the IIA in April 2016.
- What is Access For Life's current employee count?
- Access For Life currently has 1-10 employees.
- Does Access For Life have any patents?
- Yes, Access For Life holds one patent related to its technology.
- What are the target geographic markets for Access For Life?
- Access For Life targets geographic markets including Canada and Taiwan.